http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 26 May 2026 16:51:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/NANOBIOTIX+closes+global+offering%2C+raises+%24100+million/26550944.html <p>NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX) announced the completion of its global offering that raised approximately $100 million in gross proceeds.</p><p>The biotechnology company issued 2,218,467 ordinary shares and 345,099 pre-funded warrants. The offering included 225,373 ordinary shares in the form of American Depositary Shares and 33,805 additional ADSs following the full exercise of underwriters' over-allotment option.</p><p>The subscription price was set at €33.60 per ordinary share, equivalent to $38.98 per ADS based on a May 20, 2026 exchange rate. This represented a 14.92% discount to the volume weighted average price over the three trading sessions preceding the pricing.</p><p>The company plans to http://www.streetinsider.com/Corporate+News/NANOBIOTIX+closes+global+offering%2C+raises+%24100+million/26550944.html Tue, 26 May 2026 16:51:00 -0400 NANO NBTX http://www.streetinsider.com/Corporate+News/NANOBIOTIX+closes+global+offering%2C+raises+%24100+million/26550944.html <p>NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX) announced the completion of its global offering that raised approximately $100 million in gross proceeds.</p><p>The biotechnology company issued 2,218,467 ordinary shares and 345,099 pre-funded warrants. The offering included 225,373 ordinary shares in the form of American Depositary Shares and 33,805 additional ADSs following the full exercise of underwriters' over-allotment option.</p><p>The subscription price was set at €33.60 per ordinary share, equivalent to $38.98 per ADS based on a May 20, 2026 exchange rate. This represented a 14.92% discount to the volume weighted average price over the three trading sessions preceding the pricing.</p><p>The company plans to http://www.streetinsider.com/Corporate+News/NANOBIOTIX+closes+global+offering%2C+raises+%24100+million/26550944.html Tue, 26 May 2026 16:51:00 -0400 NANO NBTX http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Press+Releases/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547 http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html <p align="justify">PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “<strong>Nanobiotix</strong>” or the “<strong>Company</strong>”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “<strong>Closing</strong>”) of its global offering (the “<strong>Global Offering</strong>”), including in respect of the earlier total exercise by the underwriters of their option (the “<strong>Option</strong>”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “<strong>Additional ADSs</strong>”).</p> <p align="justify">Following the full exercise of the Option, the http://www.streetinsider.com/Globe+Newswire/NANOBIOTIX+Announces+Closing+of+Global+Offering/26550768.html Tue, 26 May 2026 16:44:00 -0400 A.15776824 A.20654500 A.20939327 A.21446405 A.50100012 NANO NBTX O.00003925 O.01217207 O.07579093 O.17222856 O.51342512 O.54189547